NYSE - BioNTech SE

Сектор: Healthcare

График котировок BioNTech SE

О компании

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I\u002FII trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I\u002FII a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I\u002FII clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc., Sanofi S.A., Genmab A\u002FS, Genevant Sciences GmbH, Eli Lilly and Company, Bayer AG, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in Mainz, Germany.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 51.13
P/BV 22.5
EV/EBITDA -80.73
Цена ао 121.52
EBITDA -0.3491

Все параметры ⇨



Название Значение Оценка
P/S 51.13 1
P/BV 22.5 1
P/E 0
EV/EBITDA -80.73 10


Название Значение Оценка
ROA, % -13.07 1
ROE, % 1.63 1


Название Значение Оценка
Div yield, % 0
DSI 0 0


Название Значение Оценка
Долг/EBITDA 10

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Институционалы Объем Доля, %
Fidelity Management & Research Company LLC 2943148 1.22
Fidelity Management & Research Company LLC 2612036 1.08
Artal Group S A 1731214 0.72
Bill & Melinda Gates Foundation 1038674 0.43
BlackRock Fund Advisors 720243 0.3
Deutsche Asset Management Investment GmbH 269668 0.11
Platinum Investment Management Ltd 212509 0.09
DJE Kapital AG 186400 0.08
ÖkoWorld Lux SA 184000 0.08
First Trust Advisors L.P. 143514 0.06
Van Eck Associates Corporation 115868 0.05
Henderson Global Investors Ltd 74710 0.03
Hauck & Aufhäuser Investment Gesellschaft SA 66600 0.03
Millington Securities, Inc. 38530 0.02
Security Investors, LLC 35602 0.01
Universal-Investment GmbH 34535 0.01
Goldman Sachs Asset Management, L.P. 34345 0.01
Industrial Alliance Investment Mgmt Inc 34000 0.01
UBS Asset Management 33697 0.01
DWS Investment S.A. 28733 0.01
Eyb&Wallwitz Vermögensmanagement GmbH 25000 0.01
Uzès Gestion 16000 0.01
PMG Fonds Management AG 16000 0.01
Bellevue Asset Management AG 15000 0.01
Exchange Traded Concepts, LLC 12564 0.01
Plutos Vermögensverwaltung AG 11500 0
ACATIS Investment GmbH 10000 0
Operadora Actinver SA de CV 9320 0
Huber,Reuss&Kollegen Vermögensverwalt 8589 0
SSGA Funds Management Inc 5500 0
Next Edge Capital Corp. 3300 0
Portfolio Invest Anlageberatung GmbH 2100 0
Ampega Investment GmbH 2020 0
Elite Fund Management 1200 0
EquBot Inc. 1186 0
Compass Investments de México SA de CV 265 0
Peroni Portfolio Advisors, Inc 200 0
WBI Investments, Inc. 25 0
Santander Private Banking Gestión SGIIC 0 0

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
ETFMG Treatments Testing and Advancements ETF 7.53 0.81
iShares Genomics Immunology and Healthcare ETF 4.11 58.33 0.27
First Trust IPOX Europe Equity Opportunities ETF 2.22 54.30 1.16
AdvisorShares Dorsey Wright ADR ETF 2.66 42.34 0.11
Loncar Cancer Immunotherapy ETF 3.56 34.63 1.02
Virtus LifeSci Biotech Products ETF 2.51 26.39 0.79

Похожие компании